SER100 in ISH

• Research type

  Research Study

• Full title

  A randomized, double-blind, placebo-controlled, cross-over, multi-center study assessing the safety, tolerability and efficacy of SER100 10 mg s.c. twice daily for 2 days in patients with Isolated Systolic Hypertension insufficiently treated with one or more anti-hypertensives.

• IRAS ID

  137172

• Contact name

  Michael Okorie

• Contact email

  Michael.Okorie@bsuh.nhs.uk

• Sponsor organisation

  Serodus ASA

• Eudract number

  2013-001227-40

• ISRCTN Number

  n/a

• REC name

  South Central - Hampshire B Research Ethics Committee

• REC reference

  13/SC/0480

• Date of REC Opinion

  6 Nov 2013

• REC opinion

  Further Information Favourable Opinion